RECAST trial compares two first-line regimens with ramucirumab for metastatic colorectal cancer — European Journal of Cancer
The randomized phase II WJOG9216G (RECAST) study compared FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer. The trial examines whether the more intensive FOLFOXIRI regimen combined with ramucirumab offers advantages over the standard FOLFIRI combination.